Research Paper Volume 13, Issue 11 pp 14999—15012

Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases

The inhibitory effects of pharmacological inhibition of USP8 in HCC in vivo. (A) USP8i significantly inhibits HepG2 growth in mice. Mice were treated with vehicle alone, USP8i (0.5 mg/kg or 1 mg/kg once per day, intraperitoneal injection). (B) Combination of USP8i and doxorubicin is superior than in inhibiting HepG2 growth in mice. Mice were treated with vehicle alone, USP8i (0.5 mg/kg once per day, intraperitoneal injection), doxorubicin (4 mg/kg once per five days, intraperitoneal injection,), or a combination of doxorubicin and USP8i. (C) USP8i significantly inhibited doxorubicin-resistant HepG2-r growth in mice. Mice were treated with vehicle alone, USP8i (0.5 mg/kg once per day, intraperitoneal injection). *p

Figure 4. The inhibitory effects of pharmacological inhibition of USP8 in HCC in vivo. (A) USP8i significantly inhibits HepG2 growth in mice. Mice were treated with vehicle alone, USP8i (0.5 mg/kg or 1 mg/kg once per day, intraperitoneal injection). (B) Combination of USP8i and doxorubicin is superior than in inhibiting HepG2 growth in mice. Mice were treated with vehicle alone, USP8i (0.5 mg/kg once per day, intraperitoneal injection), doxorubicin (4 mg/kg once per five days, intraperitoneal injection,), or a combination of doxorubicin and USP8i. (C) USP8i significantly inhibited doxorubicin-resistant HepG2-r growth in mice. Mice were treated with vehicle alone, USP8i (0.5 mg/kg once per day, intraperitoneal injection). *p<0.01, compared to control or doxorubicin.